Nuformix plc (LON:NFX – Get Free Report) shares were down 13.7% on Wednesday . The stock traded as low as GBX 0.15 ($0.00) and last traded at GBX 0.15 ($0.00). Approximately 5,700,000 shares changed hands during trading, an increase of 132% from the average daily volume of 2,452,163 shares. The stock had previously closed at GBX 0.18 ($0.00).
Nuformix Price Performance
The company has a quick ratio of 3.35, a current ratio of 1.51 and a debt-to-equity ratio of 1.17. The firm’s fifty day moving average price is GBX 0.19 and its two-hundred day moving average price is GBX 0.24. The stock has a market capitalization of £1.24 million, a PE ratio of -1.63 and a beta of 0.28.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Recommended Stories
- Five stocks we like better than Nuformix
- What is a Stock Market Index and How Do You Use Them?
- Generac Holdings Stock: Mixed Signals Leave Investors Uncertain
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Analysts and Earnings Propel the S&P 500’s Continuous Growth
- How to Calculate Retirement Income: MarketBeat’s Calculator
- CrowdStrike Stock Soars, Outpacing Palo Alto in Cybersecurity
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
